PTAB Declines to Modify Final Written Decision Despite Alleged Error

Jun 10, 2016

Reading Time : 1 min

The case started on June 25, 2013 when Petitioner Groupon filed a petition for covered business method (CBM) review of claims 1-27 and 29 of the ’516 Patent. The PTAB instituted review of all challenged claims, but with respect to claims 2-15, 20-23 and 29, it instituted review solely based on anticipation. Notably, claims 8-12, 14, and 23 depend from claim 1, and the PTAB did not institute review of claim 1 based on anticipation.

On December 17, 2014, the PTAB entered a Final Written Decision holding, among other things, that Groupon had demonstrated by a preponderance of the evidence that claims 2-15, 20-23 and 29 were unpatentable under 35 U.S.C. §102(b). Blue Calypso appealed to the Federal Circuit, but did not claim an error in the Final Written Decision with respect to claims 2-15, 20-23 and 29 being found anticipated, despite claim 1, from which they depend, not found to be anticipated. The Federal Circuit affirmed the PTAB’s decision. Subsequently, however, Blue Calypso alleged during a conference call with the PTAB that the Final Written Decision had been issued in error because there was no finding of anticipation with respect to claim 1.

After reviewing the extensive record, the PTAB concluded that Blue Calypso “had numerous opportunities, from the time of the Decision on Institution was entered, to raise the issue of whether claims 8-12, 14, and 23 are unpatentable.” Ultimately, the PTAB found persuasive in ruling for Groupon that Blue Calypso raised this issue for the first time after Federal Circuit review and “cited no authority for such a correction of a PTAB’s final decision after [the] reviewing court has decided an appeal from the PTAB’s final decision.” The PTAB, therefore, declined to make any modification to the Final Written Decision.

Groupon, Inc. v. Blue Calypso, LLC, CBM2013-00035, Paper 49 (PTAB May 26, 2016).

Share This Insight

Previous Entries

IP Newsflash

October 1, 2025

In a recent final written decision, the PTAB determined that a reference patent was not prior art, despite the petitioner’s post‑filing attempt to correct its petition. While the petitioner argued that it intended to rely on the patent application’s earlier date of publication, both the corrected petition and the expert declaration continued to reference the issued patent rather than the published application.

...

Read More

IP Newsflash

September 30, 2025

The USPTO Director recently granted a petitioner’s request for rehearing of the decision discretionarily denying institution of inter partes review, ultimately vacating the original decision, and referring the petition to the board for an institution decision.

...

Read More

IP Newsflash

September 25, 2025

In considering claims to a method of reducing cardiovascular events, the Federal Circuit held that the term a “clinically proven effective” amount did not render the claims patentable over the prior art. Specifically, the Federal Circuit held that the “clinically proven effective” amount, whether limiting or not, could not be used to distinguish the prior art because the claims also specified the exact amount of the drugs to be administered in the method. The Federal Circuit also rejected patentee’s evidence of unexpected results because that evidence was tied solely to the “clinically proven effective” limitation.

...

Read More

IP Newsflash

September 24, 2025

The Federal Circuit reversed a district court’s denial of judgment as a matter of law on non-infringement, thereby setting aside a $106 million jury verdict, after holding that prosecution history estoppel barred the patentee from asserting infringement under the doctrine of equivalents.

...

Read More

IP Newsflash

September 17, 2025

A magistrate judge in the District of Delaware issued a Report and Recommendation, that found the sole asserted claim was a “single means” claim and therefore invalid for lack of enablement. In reaching that conclusion, the magistrate judge rejected the patentee’s argument that the preamble of the claim disclosed a second element that satisfied the combination requirement of Section 112, paragraph 6 because the preamble simply recited a descriptor of the very apparatus that was the subject of the means-plus-function limitation in the body of the claim. The district court judge presiding over this case has scheduled a hearing to review the magistrate’s ruling.

...

Read More

IP Newsflash

September 9, 2025

The Federal Circuit has affirmed the PTAB’s determination that a patent challenger did not show the challenged claims were unpatentable for obviousness. The Federal Circuit concluded that substantial evidence, which included expert testimony, showed there was no motivation to combine the references.

...

Read More

IP Newsflash

August 29, 2025

In a recent order addressing four IPR proceedings, the PTAB exercised its inherent authority under 37 C.F.R. § 42.5(a) to sua sponte authorize post-hearing discovery on a potentially dispositive privity issue. The order followed a Director review decision that vacated and remanded earlier IPRs involving the same parties, patent family, and privity issue. 

...

Read More

IP Newsflash

August 29, 2025

The Patent Trial and Appeal Board denied institution of an inter partes review petition in part because it determined that a patent reference was not prior art under the common ownership exception of pre-AIA 35 U.S.C. § 103(c)(1).

...

Read More

© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.